

CART-Cell Therapy in Multiple Myeloma

Subjects: Oncology

Contributor: Claudio Cerchione

Available data on anti-BCMA CART-cell therapy has demonstrated efficacy and manageable toxicity in heavily pretreated R/R MM patients. Chimeric antigen receptor (CAR) T-cell therapy targeting B-cell maturation antigen (BCMA) represents a new strategy for the treatment of relapsed/refractory MM (R/R).

Keywords: multiple myeloma ; BCMA ; CAR T ; relapsed multiple myeloma ; refractory myeloma ; cytokine release syndrome ; neurologic toxicity

1. Introduction

Several drugs have shown activity in multiple myeloma (MM) and are available for clinical use. As a result, there are numerous regimens that use two or more of these drugs available for the treatment of newly diagnosed and refractory/relapsed MM. The major classes include alkylating agents (melphalan and cyclophosphamide), corticosteroids (dexamethasone and prednisone), immunomodulatory drugs (thalidomide, lenalidomide, and pomalidomide), and proteasome inhibitors (bortezomib, carfilzomib, and ixazomib) [1]. The treatment paradigm in MM is evolving with the introduction of various immunotherapies [2]. First came the monoclonal antibodies (mAbs), which represented a paradigm shift in treating all MM stages [3][4][5][6][7]. The initial mAbs included daratumumab, which targets CD38 on MM cells' surface [8][9], and elotuzumab, which targets SLAMF7 [10]. These new molecules were followed by isatuximab, which also targets CD38 [11]. The new agents have clearly shown significant activity and improved progression-free survival (PFS) in newly diagnosed and relapsed MM.

Other immunotherapy drugs are poised to alter the landscape of MM treatment going forward significantly. Antibody-Drug Conjugates (ADCs) represent a new platform [12] and are best exemplified by belantamab mafodotin (BM) [13]. BM is a mAb targeting B-cell maturation antigen (BCMA) linked to a microtubule-disrupting agent, monomethyl auristatin F (MMAF) [14]. BCMA is a transmembrane glycoprotein and a member of the tumor necrosis factor (TNF) receptor superfamily, and it is preferentially expressed on mature B-cells and plasma cells in MM and plays an essential role in long-term plasma cell survival. The number of surface BCMA increases with the progression of the disease. Because of the localization to plasma cells and the expression on virtually no other cell type, BCMA can represent an ideal target for MM-specific cellular therapies [15]. BM as a singleagent has been associated with a response rate >30% in patients with multiple previous lines of therapy, including those who do not respond to PIs, IMiDs, and mAbs. The drug is now being studied in combination with other agents in both upfront and relapsed settings. Besides, several other conjugate drugs targeting BCMA are under investigation in clinical trials [16].

Another platform that has shown significant activity in patients with MM is bispecific antibodies (BiAbs) [17]. BiAbs are designed to bring T-cells closer to the tumor cell by targeting both cell types simultaneously, promoting a more robust T-cell response and immune synapse formation to eliminate MM cells. With BiAbs, investigators reported few CRS rates, easy management, and very little neurotoxicity.

And last but not least, CAR T-cells. CAR T-cell transplantation technology has evolved dramatically during the past 25 years ([Figure 1](#)) [18][19][20][21][22]. The current version of BCMA-directed CAR T-cell therapy employs a construct with a single-chain variable fragment that recognizes the BCMA antigen, a spacer, an intracellular co-stimulatory signaling domain (often 4-1BB), and a CD3ζ intracellular domain to stimulate T-cell activation upon binding ([Figure 2](#)). The initial wave of CAR T-cells that target BCMA has shown remarkable efficacy in MM.




Figure 1. CAR T manufacturing process.




Figure 2. BCMA CAR T-cell Contract Design.

2. Anti-BCMACAR T-Cell Studies

Outcomes for patients with triple-exposed relapsed or refractory (R/R) MM have been poor, with a median PFS of only 3 to 4 months [23]. Among R/R MM patients who have been exposed to IMIDs, PIs, mAbs, and have received multiple lines of therapy, there are no standard-of-care options. Often, the choice of treatment we offer is based on the availability of the utmost efficacious agent. Interest in CAR T-cell therapy in MM has been high, especially for products targeting BCMA. Several BCMA-targeted CAR T-cell therapies are in clinical development for patients with R/R MM, and trials' results are published or presented at the most recent international congresses ([Table 1](#) and [Table 2](#)).

Table 1. Anti-BCMACAR T-Cell Studies: Main Patients' characteristics.

	Idecabtagene Vicleucel (bb2121)	Ciltacabtagene Autoleucel (JNJ-4528)	Orvacabtagene Autoleucel (JCAR-H125)	Idecabtagene Vicleucel (ide-cel, bb2121)
Author (year)	Munshi (2020) Alsina (2020)	Berdeja (2019) Madduri (2020)	Berdeja (2020) Mailankody (2020)	Lin (2020)
Reference	[24]	[25][26]	[27][28]	[29][30] [31]
Study Name	KarMMa	CRB-402	CARTITUDE-1	EVOLVE

	Idecabtagene Vicleucel (bb2121)	Ciltacabtagene Autoleucel (JNJ-4528)	Orvacabtagene Autoleucel (JCAR-H125)	Idecabtagene Vicleucel (ide-cel, bb2121)
Construct	The ide-cel CAR is comprised of a murine extracellular single-chain variable fragment (scFv) specific for recognizing BCMA, attached to a human CD8 α hinge and transmembrane domain fused to the T-cell cytoplasmic signaling domains of CD137 4-1BB and CD3-ζ chain, in tandem	Cells engineered with bb2121 construct are then ex vivo cultured with PI3K inhibitor bb007	2 BCMA-targeting single-domain antibodies to boost avidity plus a 4-1BB co-stimulatory domain	Comprising fully human BCMA-binding domain with low affinity for soluble BCMA, 4-1BB co-stimulatory domain, CD3ζ signaling domain
Median Age	61 (range 33–78)	62 (range, 33–74)	61 (range, 43–78)	61 (range, 33–77)
Cell Dose × 10⁶ kg	150 300 450 150 300 450	0.75	300 450 600	50, 150, 450, or 800 × 10 ⁶ in the dose-escalation phase 150 to 450 × 10 ⁶ in the dose-expansion phase.
No. Patients	4 70 55 12 28 20	97 (29 phase I ^b /68 phase II)	19 18 7	21 patients dose-escalation phase; 41 dose-expansion phase.
Lymphodepletion	FLU + CY	FLU + CY	FLU + CY	FLU + CY
Median Followup	13.3	8.5	11.5	9.5 8.8 2.3 14.7

B-cell maturation antigen (BCMA); Lymphodepletion consisted of Fludarabine (FLU) 30 mg/m² × 3 days + Cyclophosphamide (CY) 300 mg/m² × 3 days

Table 2. anti-BCMA CAR T-Cell Studies: outcomes.

Car t Cell Construct	Idecabtagene Vicleucel (bb2121)	Ciltacabtagene Autoleucel (JNJ-4528)	Orvacabtagene Autoleucel (JCAR-H125)	Idecabtagene Vicleucel (ide-cel, bb2121)
Author (Year)	Munshi (2020) Berdeja (2019) Alsina (2020)	Berdeja (2020) Madduri (2020)	Mailankody (2020)	Lin (2020)
Study Name	KarMMA CRB-402	CARTITUDE-1	EVOLVE	CRB-401
Reference				
	[24]	[25][26]	[27][28]	[29][30]
Response Rate				
ORR	50% 69% 82% 83% 43% 73%	97%	95%	89% 92% 76(%)
CR	25% 29% 39%	18%	67%	37% 42% 29% 39(%)
Median DoR	NR 9.9 11.3	11.9	NR	NR NR NR 10.3(%)
Median PFS	2.8 5.8 12.1	NR NR NR	NR	9.3 NR NR 8.8 (%)
Evaluable for MRD	4 70 54	7 6 4	57	11 11 3 37
MRD-	50% 31% 48% 100% 83.3% 100%	93%	72.7% 90.9%	100% 81%
CRS Event				
All	50% 76% 96%	67%	94.8%	89% 76(%)
Median Time to First Onset	7 (2–12) 2 (1–12) 1 (1–10)	3 (1–20)	7 (1–12)	2 (1–4) Nk
Grade 3–4	0 4% 6%	2%	4%	3% 6(%)
Grade 5	0 1% 0	2%	1%	0 0
Neurotoxicities				
All	0 17% 20%	22%	20.6%	13% 44%

Car t Cell Construct	Idecabtagene Vicleucel (bb2121)	Ciltacabtagene Autoleucel (JNJ-4528)	Orvacabtagene Autoleucel (JCAR-H125)	Idecabtagene Vicleucel (ide-cel, bb2121)
----------------------	------------------------------------	---	---	--

References

1. Rajkumar, S.V.; Kumar, S.³. Multiple myeloma current treatment algorithms. *Blood Cancer J.* 2020, 10, 1–10.
2. Kumar, S.K.; Callander, N.S.; Adekola, K.; Anderson, L.; Baljevic, M.; Campagnaro, E.; Castillo, J.J.; Chandler, J.C.; Costello, C.; Efebera, Y.; et al. Multiple Myeloma, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology. *J. Natl. Compr. Cancer Netw.* 2020, 18, 1685–1717.
3. Bonello, F.; Grasso, M.; D'Agostino, M.; Celeghini, I.; Castellino, A.; Boccadoro, M.; Bringhen, S. The Role of Monoclonal Antibodies in the First-Line Treatment of Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma. *Pharmaceuticals* 2020, 14, 20.
4. Park, S.; Byun, J.M.; Yoon, S.; Kim, K.; Jung, S.; Lee, J.; Min, C. Daratumumab monotherapy for relapsed/refractory multiple myeloma, focussed on clinical trial-unfit patients and subsequent therapy. *Br. J. Haematol.* 2021, 193, 101–112.
5. Richter, J.; Thibaudeau, S. Anti-body building: The exercise of advancing immune based myeloma therapies. *Blood Rev.* 2020, 100789.
6. Zamagni, Z.; Tacchetti, T.; Deias, D.; Patriarca, P. The Role of Monoclonal Antibodies in Smoldering and Newly Diagnosed Transplant-Eligible Multiple Myeloma. *Pharmaceuticals* 2020, 13, 451.
7. Morè, S.; Petrucci, M.T.; Corvatta, L.; Fazio, F.; Offidani, M.; Olivieri, A. Monoclonal Antibodies: Leading Actors in the Relapsed/Refractory Multiple Myeloma Treatment. *Pharmaceuticals* 2020, 13, 426.
8. Chong, L.L.; Soon, Y.Y.; Soekojo, C.Y.; Ooi, M.; Chng, W.J.; de Mel, S. Daratumumab-based induction therapy for multiple myeloma: A systematic review and meta-analysis. *Crit. Rev. Oncol.* 2021, 159, 103211.
9. Richard, S.; Jagannath, S.; Cho, H.J.; Parekh, S.; Madduri, D.; Richter, J.; Chari, A. A comprehensive overview of daratumumab and carfilzomib and the recently approved daratumumab, carfilzomib and dexamethasone regimen in relapsed/refractory multiple myeloma. *Expert Rev. Hematol.* 2021, 14, 31–45.
10. Dimopoulos, M.A.; Lonial, S.; White, D.; Moreau, P.; Weisel, K.; San-Miguel, J.; Shpilberg, O.; Grosicki, S.; Špička, I.; Walter-Croneck, A.; et al. Elotuzumab, lenalidomide, and dexamethasone in RRMM: Final overall survival results from the phase 3 randomized ELOQUENT-2 study. *Blood Cancer J.* 2020, 10, 1–10.
11. Richardson, P.G.; Beksaç, M.; Špička, I.; Mikhael, J. Isatuximab for the treatment of relapsed/refractory multiple myeloma. *Expert Opin. Biol. Ther.* 2020, 20, 1395–1404.
12. McMillan, A.; Warcel, D.; Popat, R. Antibody-drug conjugates for multiple myeloma. *Expert Opin. Biol. Ther.* 2020, 12, 1–13.
13. Sheikh, S.; Lebel, E.; Trudel, S. Belantamab mafodotin in the treatment of relapsed or refractory multiple myeloma. *Future Oncol.* 2020, 16, 2783–2798.
14. Yu, B.; Jiang, T.; Liu, D. BCMA-targeted immunotherapy for multiple myeloma. *J. Hematol. Oncol.* 2020, 13, 125.
15. Carpenter, R.O.; Ebuomwan, M.O.; Pittaluga, S.; Rose, J.J.; Raffeld, M.; Yang, S.; Gress, R.E.; Hakim, F.T.; Kochenderfer, J.N. B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma. *Clin. Cancer Res.* 2013, 19, 2048–2060.
16. Verkleij, C.; Frerichs, K.A.; Broekmans, M.; Absalah, S.; Maas-Bosman, P.; Kruyswijk, S.; Nijhof, I.S.; Mutis, T.; Zweegman, S.; van de Donk, N. T-cell redirecting bispecific antibodies targeting BCMA for the treatment of multiple myeloma. *Oncotarget* 2020, 11, 4076–4081.
17. Palma, B.; Marchica, V.; Catarozzo, M.T.; Giuliani, N.; Accardi, F. Monoclonal and Bispecific Anti-BCMA Antibodies in Multiple Myeloma. *J. Clin. Med.* 2020, 9, 3022.
18. Wudhikarn, K.; Mailankody, S.; Smith, E.L. Future of CAR T cells in multiple myeloma. *Hematol. Am. Soc. Hematol. Educ. Program* 2020, 2020, 272–279.
19. Roex, G.; Timmers, M.; Wouters, K.; Campillo-Davo, D.; Flumens, D.; Schroyens, W.; Chu, Y.; Berneman, Z.N.; Lion, E.; Luo, F.; et al. Safety and clinical efficacy of BCMA CAR-T-cell therapy in multiple myeloma. *J. Hematol. Oncol.* 2020, 13, 164.
20. Rodríguez-Otero, P.; Prósper, F.; Alfonso, A.; Paiva, B.; San Miguel, J.F. CAR T-Cells in Multiple Myeloma Are Ready for Prime Time. *J. Clin. Med.* 2020, 9, 3577.

21. Rana, J.; Biswas, M. Regulatory T cell therapy: Current and future design perspectives. *Cell Immunol.* 2020, 356, 104193.
22. Nadeem, O.; Tai, Y.T.; Anderson, K.C. Immunotherapeutic and Targeted Approaches in Multiple Myeloma. *Immunotargets Ther.* 2020, 9, 201–215.
23. Gandhi, U.H.; Cornell, R.F.; Lakshman, A.; Gahvari, Z.J.; McGehee, E.; Jagosky, M.H.; Gupta, R.; Varnado, W.; Fiala, M.A.; Chhabra, S.; et al. Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. *Leukemia* 2019, 33, 2266–2275.
24. Munshi, N.C.; Anderson, L.D.; Shah, N.; Jagannath, S.; Berdeja, J.G.; Lonial, S.; Raje, N.S.; Siegel, D.S.; Lin, Y.; Oriol, A.; et al. Idecabtagenevicleucel, a BCMA-targeted CAR T-cell therapy, in patients with relapsed and refractory multiple myeloma: Initial KarMMa results. *J. Clin. Oncol.* 2020, 38 (Suppl. S15), 8503.
25. Berdeja, J.G.; Alsina, M.; Shah, N.; Siegal, D.S.; Jagannath, S.; Madduri, D.; Kaufman, J.L.; Munshi, N.C.; Rosenblatt, J.; Jasielec, J.K.; et al. Updated Results from an Ongoing Phase 1 Clinical Study of bb21217 Anti-Bcma CAR T Cell Therapy. *Blood* 2019, 134 (Suppl. 1), 927.
26. Alsina, M.; Shah, N.; Raje, N.S.; Jagannath, S.; Madduri, D.; Kaufman, J.L.; Siegel, D.S.; Munshi, N.C.; Rosenblatt, J.; Lin, Y.; et al. Updated Results from the Phase I CRB-402 Study of Anti-Bcma CAR-T Cell Therapy bb21217 in Patients with Relapsed and Refractory Multiple Myeloma: Correlation of Expansion and Duration of Response with T Cell Phenotypes. *Blood* 2020, 136 (Suppl. 1), 25–26.
27. Berdeja, J.G.; Madduri, D.; Usmani, S.Z.; Singh, I.; Zudaire, E.; Yeh, T.M.; Allred, A.J.; Olyslager, Y.; Banerjee, A.; Goldberg, J.D.; et al. Update of CARTITUDE-1: A phase Ib/II study of JNJ-4528, a B-cell maturation antigen-directed CAR-T-cell therapy, in relapsed/refractory multiple myeloma. *J. Clin. Oncol.* 2020, 38 (Suppl. S15), 8505.
28. Madduri, D.; Berdeja, J.G.; Usmani, S.Z.; Jakubowiak, A.; Agha, M.; Cohen, A.; Stewart, A.K.; Hari, P.; Htut, M.; O'Donnell, E.; et al. CARTITUDE-1: Phase 1b/2 study of ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T cell therapy, in relapsed/refractory multiple myeloma. *Blood* 2020, 136 (Suppl. S1), 22–25.
29. Mailankody, S.; Htut, M.; Lee, K.P.; Bensinger, W.; Devries, T.; Piasecki, J.; Ziyad, S.; Blake, M.; Byon, J.; Jakubowiak, A. JCARH125, anti-BCMA CAR T-cell therapy for relapsed/refractory multiple myeloma: Initial proof of concept results from a phase 1/2 multicenter study (EVOLVE). *Blood* 2018, 132 (Suppl. S1), 957.
30. Mailankody, S.; Jakubowiak, A.J.; Htut, M.; Costa, L.J.; Lee, K.; Ganguly, S.; Kaufman, J.L.; Siegel, D.S.; Bensinger, W.; Cota, M.; et al. Orvacabtageneautoleucel (orva-cel), a B-cell maturation antigen (BCMA)-directed CAR T cell therapy for patients (pts) with relapsed/refractory multiple myeloma (RRMM): Update of the phase 1/2 EVOLVE study (NCT03430011). *J. Clin. Oncol.* 2020, 38 (Suppl. S15), 8504.
31. Lin, Y.; Raje, N.S.; Berdeja, J.G.; Siegel, D.S.; Jagannath, S.; Madduri, D.; Liedtke, M.; Rosenblatt, J.; Maus, M.V.; Massaro, M.; et al. Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-Directed CAR T Cell Therapy, in Patients with Relapsed and Refractory Multiple Myeloma: Updated Results from Phase 1 CRB-401. *Blood* 2020, 136 (Suppl. S1), 26–27.

Retrieved from <https://encyclopedia.pub/entry/history/show/25905>